

Taryn L Mayes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5263919/publications.pdf>

Version: 2024-02-01

108
papers

5,735
citations

76326

40
h-index

79698

73
g-index

109
all docs

109
docs citations

109
times ranked

5068
citing authors

#	ARTICLE	IF	CITATIONS
1	Suicide Attempts and Nonsuicidal Self-Injury in the Treatment of Resistant Depression in Adolescents: Findings from the TORDIA Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2011, 50, 772-781.	0.5	460
2	Anhedonia Predicts Poorer Recovery Among Youth With Selective Serotonin Reuptake Inhibitor Treatment—Resistant Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2012, 51, 404-411.	0.5	337
3	Predictors of Spontaneous and Systematically Assessed Suicidal Adverse Events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) Study. <i>American Journal of Psychiatry</i> , 2009, 166, 418-426.	7.2	198
4	Recovery and Recurrence Following Treatment for Adolescent Major Depression. <i>Archives of General Psychiatry</i> , 2011, 68, 263.	12.3	183
5	Protecting Adolescents From Self-Harm: A Critical Review of Intervention Studies. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 1260-1271.	0.5	179
6	Treatment of Selective Serotonin Reuptake Inhibitor-Resistant Depression in Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 330-339.	0.5	173
7	Review of the efficacy and safety of antidepressants in youth depression. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2005, 46, 735-754.	5.2	163
8	Treatment for Adolescents With Depression Study (TADS). <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 1440-1455.	0.5	162
9	Psychometric Properties of the Children's Depression Rating Scale—Revised in Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 513-516.	1.3	162
10	Treatment of Resistant Depression in Adolescents (TORDIA): Week 24 Outcomes. <i>American Journal of Psychiatry</i> , 2010, 167, 782-791.	7.2	159
11	Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents. <i>American Journal of Psychiatry</i> , 2008, 165, 459-467.	7.2	156
12	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. <i>Psychoneuroendocrinology</i> , 2017, 78, 105-113.	2.7	155
13	Fluoxetine in child and adolescent depression: Acute and maintenance treatment. <i>Depression and Anxiety</i> , 1998, 7, 32-39.	4.1	147
14	Association of FKBP5 Polymorphisms With Suicidal Events in the Treatment of Resistant Depression in Adolescents (TORDIA) Study. <i>American Journal of Psychiatry</i> , 2010, 167, 190-197.	7.2	128
15	Sequential Treatment With Fluoxetine and Relapse-Prevention CBT to Improve Outcomes in Pediatric Depression. <i>American Journal of Psychiatry</i> , 2014, 171, 1083-1090.	7.2	119
16	Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. <i>Journal of Affective Disorders</i> , 2018, 233, 3-14.	4.1	116
17	The Treatment for Adolescents With Depression Study (TADS): Outcomes Over 1 Year of Naturalistic Follow-Up. <i>American Journal of Psychiatry</i> , 2009, 166, 1141-1149.	7.2	114
18	Brain Activity in Adolescent Major Depressive Disorder Before and After Fluoxetine Treatment. <i>American Journal of Psychiatry</i> , 2012, 169, 381-388.	7.2	108

#	ARTICLE	IF	CITATIONS
19	Suicidal Events in the Treatment for Adolescents With Depression Study (TADS). <i>Journal of Clinical Psychiatry</i> , 2009, 70, 741-747.	2.2	108
20	Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. <i>International Journal of Methods in Psychiatric Research</i> , 2010, 19, 185-194.	2.1	104
21	Long-Term Outcome of Adolescent Depression Initially Resistant to Selective Serotonin Reuptake Inhibitor Treatment. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 388-396.	2.2	102
22	Cognitive-Behavioral Therapy to Prevent Relapse in Pediatric Responders to Pharmacotherapy for Major Depressive Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2008, 47, 1395-1404.	0.5	89
23	A Cross-Cultural Investigation of Cognitions and Depressive Symptoms in Adolescents.. <i>Journal of Abnormal Psychology</i> , 2004, 113, 248-257.	1.9	83
24	Sleep polysomnography as a predictor of recurrence in children and adolescents with major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 159-68.	2.1	79
25	Impact of Physical and Sexual Abuse on Treatment Response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2011, 50, 293-301.	0.5	76
26	Hopelessness and suicidal ideation among adolescents in two cultures. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2005, 46, 364-372.	5.2	69
27	Depressive Symptoms and Clinical Status During the Treatment of Adolescent Suicide Attempters (TASA) Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 997-1004.	0.5	68
28	Mood disorders in children and adolescents: psychopharmacological treatment. <i>Biological Psychiatry</i> , 2001, 49, 1082-1090.	1.3	67
29	Insomnia Moderates Outcome of Serotonin-Selective Reuptake Inhibitor Treatment in Depressed Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 21-28.	1.3	64
30	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. <i>Brain, Behavior, and Immunity</i> , 2017, 66, 103-110.	4.1	60
31	Acute Time to Response in the Treatment for Adolescents With Depression Study (TADS). <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 1412-1418.	0.5	57
32	The use of antidepressants to treat depression in children and adolescents. <i>Cmaj</i> , 2006, 174, 193-200.	2.0	56
33	Substance Use and the Treatment of Resistant Depression in Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 1182-1192.	0.5	54
34	Predictors of response to treatment in children and adolescents with mood disorders. <i>Psychiatric Clinics of North America</i> , 2003, 26, 435-456.	1.3	52
35	Early Prediction of Acute Antidepressant Treatment Response and Remission in Pediatric Major Depressive Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 71-78.	0.5	50
36	Preliminary Examination of the Interpersonal Psychological Theory of Suicide in an Adolescent Clinical Sample. <i>Journal of Abnormal Child Psychology</i> , 2016, 44, 1133-1144.	3.5	48

#	ARTICLE	IF	CITATIONS
37	Onset of alcohol or substance use disorders following treatment for adolescent depression.. Journal of Consulting and Clinical Psychology, 2012, 80, 299-312.	2.0	46
38	Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study. Journal of Affective Disorders, 2012, 138, 86-95.	4.1	45
39	The Bi-Directional Relationship Between Parent-Child Conflict and Treatment Outcome in Treatment-Resistant Adolescent Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 370-377.	0.5	45
40	Relapse and Recurrence in Pediatric Depression. Child and Adolescent Psychiatric Clinics of North America, 2006, 15, 1057-1079.	1.9	44
41	Incremental Cost-effectiveness of Combined Therapy vs Medication Only for Youth With Selective Serotonin Reuptake Inhibitor-Resistant Depression. Archives of General Psychiatry, 2011, 68, 253.	12.3	43
42	Pharmacokinetically and Clinician-Determined Adherence to an Antidepressant Regimen and Clinical Outcome in the TORDIA Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 490-498.	0.5	41
43	Neuroleptic Malignant Syndrome Associated With Atypical Antipsychotics in Pediatric Patients. Journal of Clinical Psychiatry, 2008, 69, 1157-1165.	2.2	40
44	Continuation and Maintenance Therapy of Early-Onset Major Depressive Disorder. Paediatric Drugs, 2005, 7, 203-217.	3.1	37
45	Do Children and Adolescents Have Differential Response Rates in Placebo-Controlled Trials of Fluoxetine?. CNS Spectrums, 2007, 12, 147-154.	1.2	34
46	Development and Implementation of Health and Wellness CBT for Individuals With Depression and HIV. Cognitive and Behavioral Practice, 2014, 21, 237-246.	1.5	34
47	Assessment of Safety and Long-Term Outcomes of Initial Treatment With Placebo in TADS. American Journal of Psychiatry, 2009, 166, 337-344.	7.2	33
48	Effective Treatment of Depressive Disorders in Medical Clinics for Adolescents and Young Adults Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 38-46.	2.1	33
49	Sleep microarchitecture as a predictor of recurrence in children and adolescents with depression. International Journal of Neuropsychopharmacology, 2002, 5, 217-28.	2.1	32
50	Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality. Journal of Affective Disorders, 2018, 235, 45-51.	4.1	32
51	Maternal Depressive Symptoms in Pediatric Major Depressive Disorder: Relationship to Acute Treatment Outcome. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 694-699.	0.5	31
52	Treatment-Resistant Depressed Youth Show a Higher Response Rate if Treatment Ends During Summer School Break. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 1140-1148.	0.5	31
53	Depression in Children and Adolescents. CNS Drugs, 1999, 11, 181-189.	5.9	28
54	The Development and Feasibility Outcomes of a Youth Suicide Prevention Intensive Outpatient Program. Journal of Adolescent Health, 2019, 64, 362-369.	2.5	28

#	ARTICLE	IF	CITATIONS
55	Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 991-998.	0.5	27
56	Symptom Improvement and Residual Symptoms during Acute Antidepressant Treatment in Pediatric Major Depressive Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 423-430.	1.3	26
57	Dysfunctional adaptive immune response in adolescents and young adults with suicide behavior. <i>Psychoneuroendocrinology</i> , 2020, 111, 104487.	2.7	26
58	Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial. <i>Journal of Psychiatric Research</i> , 2017, 94, 1-6.	3.1	23
59	Predictors of Treatment Response in Adolescent Depression. <i>Pediatric Annals</i> , 2011, 40, 300-306.	0.8	22
60	The Bidirectional Relationship Between Body Mass Index and Treatment Outcome in Adolescents with Treatment-Resistant Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 458-467.	1.3	22
61	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). <i>Journal of Psychiatric Research</i> , 2020, 122, 22-32.	3.1	21
62	Anxiety As a Predictor of Treatment Outcome in Children and Adolescents with Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 211-216.	1.3	20
63	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. <i>Translational Psychiatry</i> , 2021, 11, 513.	4.8	20
64	Treatment of children With antidepressants: Focus on selective serotonin reuptake inhibitors. , 1998, 8, 13-17.		17
65	A SPECT HMPAO study of regional cerebral blood flow in depressed adolescents and normal controls. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1999, 23, 643-656.	4.8	17
66	Structured Interview and Uniform Assessment Improves Diagnostic Reliability. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2000, 10, 119-131.	1.3	16
67	A Comparison of Various Methods of Measuring Antidepressant Medication Adherence Among Children and Adolescents with Major Depressive Disorder in a 12-Week Open Trial of Fluoxetine. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 431-439.	1.3	15
68	Impact of Treatments for Depression on Comorbid Anxiety, Attentional, and Behavioral Symptoms in Adolescents With Selective Serotonin Reuptake Inhibitor-Resistant Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 482-492.	0.5	15
69	Treatment of Selective Serotonin Reuptake Inhibitor-Resistant Depression in Adolescents: Predictors and Moderators of Treatment Response. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 330-339.	0.5	14
70	Childhood Depression Subscales Using Repeated Sessions on Children's Depression Rating Scale - Revised (CDRS-R) Scores. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 318-324.	1.3	14
71	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. <i>Journal of Psychiatric Research</i> , 2018, 102, 65-71.	3.1	14
72	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. <i>Journal of Psychopharmacology</i> , 2019, 33, 185-193.	4.0	14

#	ARTICLE	IF	CITATIONS
73	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2020, 126, 19-25.	3.1	14
74	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. <i>Neuropsychopharmacology</i> , 2021, 46, 1272-1282.	5.4	14
75	Predictors and Moderators of Relapse in Children and Adolescents With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 15m10330.	2.2	14
76	Efficacy of a Behavioral Activation Teletherapy Intervention to Treat Depression and Anxiety in Primary Care VitalSign<sup>6</sup></sup> Program. primary care companion for CNS disorders, The, 2017, 19, .	0.6	14
77	Adjunctive tDCS for treatment-refractory auditory hallucinations in schizophrenia: A meta-analysis of randomized, double-blinded, sham-controlled studies. <i>Asian Journal of Psychiatry</i> , 2022, 73, 103100.	2.0	14
78	Experiencing bullying's impact on adolescent depression and anxiety: Mediating role of adolescent resilience. <i>Journal of Affective Disorders</i> , 2022, 310, 477-483.	4.1	14
79	Depression. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2012, 21, 807-829.	1.9	13
80	UPDATES IN THE PHARMACOLOGIC TREATMENT OF CHILDHOOD DEPRESSION. <i>Psychiatric Clinics of North America</i> , 2000, 23, 813-835.	1.3	12
81	Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. <i>Molecular Neuropsychiatry</i> , 2018, 4, 7-19.	2.9	12
82	Treatment of children With antidepressants: Focus on selective serotonin reuptake inhibitors. <i>Depression and Anxiety</i> , 1998, 8, 13-17.	4.1	12
83	Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS). <i>Journal of Psychiatric Research</i> , 2015, 68, 346-353.	3.1	10
84	Dysfunction of default mode network is associated with active suicidal ideation in youths and young adults with depression: Findings from the T-RAD study. <i>Journal of Psychiatric Research</i> , 2021, 142, 258-262.	3.1	10
85	Sex-specific differences in the association between body mass index and brain aging in young adults: Findings from the human connectome project. <i>Psychoneuroendocrinology</i> , 2021, 124, 105059.	2.7	8
86	Socioeconomic Predictors of Treatment Outcomes Among Adults With Major Depressive Disorder. <i>Psychiatric Services</i> , 2022, 73, 965-969.	2.0	8
87	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 412.	2.5	7
88	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	6
89	The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. <i>Translational Psychiatry</i> , 2021, 11, 531.	4.8	6
90	Childhood Depression: Diagnosis and Treatment Strategies in General Pediatrics. <i>Pediatric Annals</i> , 2001, 30, 130-137.	0.8	5

#	ARTICLE	IF	CITATIONS
91	A primary care first (PCP-first) model to screen and treat depression: A VitalSign6 report from a second cohort of 32,106 patients. <i>General Hospital Psychiatry</i> , 2022, 74, 1-8.	2.4	5
92	The network analysis of depressive symptoms before and after two weeks of antidepressant treatment. <i>Journal of Affective Disorders</i> , 2022, 299, 126-134.	4.1	5
93	Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory. <i>Translational Psychiatry</i> , 2022, 12, 16.	4.8	5
94	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2022, 149, 243-251.	3.1	4
95	Youth Aware of Mental Health (YAM) Program With Texas Adolescents. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	2.2	4
96	Suicide Attempts and Nonsuicidal Self-Injury in the Treatment of Resistant Depression in Adolescents: Findings from the TORDIA Study. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 380-388.	0.8	2
97	Understanding the Impact of Treatment on the Dimensions of Childhood Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 160-166.	1.3	2
98	Predictors of Treatment Response in Adolescent Depression. <i>Psychiatric Annals</i> , 2011, 41, 213-219.	0.1	2
99	Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2022, 63, 1347-1358.	5.2	2
100	Depression in children and adolescents: optimizing treatment. <i>Pediatric Health</i> , 2007, 1, 217-232.	0.3	1
101	Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 348-357.	0.8	1
102	Cognitive Behavioral Therapy in Youth: An Update. <i>Psychiatric Annals</i> , 2011, 41, 226-231.	0.1	1
103	Outpatient diagnosis and clinical presentation of bipolar youth. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2009, 18, 215-20.	0.6	1
104	A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 278-287.	1.3	1
105	Addressing adherence to antidepressant treatment for depression. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 125-126.	1.7	0
106	Pharmacotherapy for Pediatric Major Depression. <i>Psychiatric Annals</i> , 2010, 40, 192-202.	0.1	0
107	Cognitive Behavioral Treatment of Depression in Youth. <i>Pediatric Annals</i> , 2011, 40, 307-313.	0.8	0
108	Accelerated Brain Aging in Major Depressive Disorder Predicts Poorer Treatment Outcomes with Sertraline: Findings From the EMBARC Study. <i>Biological Psychiatry</i> , 2022, 91, S4.	1.3	0